TriangleNCT04484142 · CITED IN SOURCE DOCUMENTS
Study of DS-1062a in Advanced or Metastatic Non-small Cell Lung Cancer With Actionable Genomic Alterations (TROPION-Lung05)
An NCI or FDA source cites this study. A citation does not establish that it applies to an individual diagnosis.
- Phase
- PHASE2
- Status at capture
- COMPLETED
- Registry last update
- 2026-03-24
This is a study of the efficacy, pharmacokinetics, and safety of DS-1062a in participants with advanced or metastatic non-small cell lung cancer (NSCLC) with known actionable genomic alterations.
Open the original ClinicalTrials.gov record → · Download preserved record
What did the study report?
Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.
Participant flow
Baseline characteristics
Percentage of Participants With Objective Response Rate (ORR) Based on Blinded Independent Central Review (BICR)
Duration of Response (DOR)
Progression-free Survival (PFS)
Overall Survival (OS)
Pharmacokinetic Parameter Maximum Concentration (Cmax)
Pharmacokinetic Parameter Time to Maximum Concentration (Tmax)
Pharmacokinetic Parameter Area Under the Concentration-Time Curve (AUC)
Percentage of Participants Who Reported Treatment-emergent Adverse Events (TEAE)
Adverse events
Limitations, agreements, and source contact
Who could take part
- eligibility Criteria
- Inclusion Criteria: Participants eligible for inclusion in the study must meet all inclusion criteria for this study. * Sign and date the inform consent form (ICF) prior to the start of any study- specific qualification procedures. * Adults ≥18 years (if the legal age of consent is \>18 years old, then follow local regulatory requirements) * Has pathologically documented NSCLC that: 1. Has stage IIIB, IIIC, or stage IV NSCLC disease at the time of enrollment (based on the American Joint Committee on Cancer, Eighth Edition). 2. Has one or more of the following documented activating genomic alterations: EGFR, ALK, ROS1, NTRK, BRAF, MET exon 14 skipping, or RET. KRAS mutations in the absence of any of the genomic alterations specified above will be excluded. Overexpression of EGFR, in the absence of activating mutations, is NOT sufficient for enrollment. Participants who have not received osimertinib should be evaluated for the presence of EGFR T790M mutation after relapse/progression on/after the most recent EGFR tyrosine kinase inhibitor (TKI), unless the participant is already known to be positive with document results for this mutation or unless osimertinib is not locally approved. * Has documentation of radiographic disease progression while on or after receiving the most recent treatment regimen for advanced or metastatic NSCLC. * Participant must meet the following for advanced or metastatic NSCLC: 1. Has been treated with at least one but no more than two cytotoxic agent-containing therapy in the metastatic setting: * One platinum-containing regimen (either as monotherapy or combination therapy). * May have received up to one additional line of cytotoxic agent-containing therapy. * Those who received a platinum-containing regimen as adjuvant therapy for early stage disease must have relapsed or progressed while on the treatment or within 6 months of the last dose OR received at least one additional course of platinum-containing therapy (which may or may not be same as in the adjuvant setting) for relapsed/progressive disease. 2. May have received up to one checkpoint inhibitor (CPI)-containing regimen (may be in combination with a cytotoxic agent as part of a regimen described above or as an additional CPI regimen without a cytotoxic agent). 3. Has been treated with 1 or more lines of non-CPI targeted therapy that is locally approved for the participant's applicable genomic alteration at the time of screening: * Those who received a targeted agent for the applicable genomic alterations in the study as adjuvant therapy for early stage disease must have relapsed or progressed while on the treatment or within 6 months of the last dose OR received at least one additional course of targeted therapy for the same genomic alterations (which may or may not be same agent used in the adjuvant setting) for relapsed/progressive disease. * Participants who have been treated with a prior TKI must receive additional targeted therapy, if clinically appropriate, for the genomic alterations that are considered amenable or the participant will not be allowed in the study. * Must undergo a mandatory pre-treatment tumor biopsy procedure or if available, a tumor biopsy that was recently collected (within 3 months of screening) after completion of the most recent anticancer treatment regimen and that has a minimum of 10 × 4 micron sections or a tissue block equivalent of 10 × 4 micron sections may be substituted for the mandatory biopsy collected during screening. * Measurable disease based on local imaging assessment using RECIST v1.1. * Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 - 1 at screening. Exclusion Criteria: Participants meeting any exclusion criteria for this study will be excluded from this study. * Has spinal cord compression or clinically active central nervous system metastases, defined as untreated and symptomatic, or requiring therapy with corticosteroids or anticonvulsants to control associated symptoms. Participants with clinically inactive brain metastases may be included in the study. * Has leptomeningeal carcinomatosis. * Has prior treatment with: 1. Any chemotherapeutic agent targeting topoisomerase I, including antibody drug conjugate (ADC) containing such agent. 2. TROP2-targeted therapy. * Uncontrolled or significant cardiovascular disease: 1. History of myocardial infarction within 6 months prior to Cycle 1 Day 1. 2. History of uncontrolled angina pectoris within 6 months prior to Cycle 1 Day 1. 3. Symptomatic congestive heart failure (CHF) (New York Heart Association Class II to IV) at screening. Participants with a history of Class II to IV CHF prior to screening must have returned to Class I CHF and have LVEF ≥50% (by either an ECHO or MUGA scan within 28 days of Cycle 1 Day 1) in order to be eligible. 4. History of serious cardiac arrhythmia requiring treatment. 5. LVEF \<50% or institutional lower limit of normal by ECHO or MUGA scan. 6. Uncontrolled hypertension (resting systolic blood pressure \>180 mmHg or diastolic blood pressure \>110 mmHg). * Has a history of (non-infectious) interstitial lung disease (ILD)/pneumonitis that required steroids, has current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at screening. * Clinically severe pulmonary compromise resulting from intercurrent pulmonary illnesses * Clinically significant corneal disease. * Has other primary malignancies, except adequately resected non-melanoma skin cancer, curatively treated in situ disease, or other solid tumors curatively treated, with no evidence of disease for ≥3 years.
- healthy Volunteers
- false
- minimum Age
- 18 Years
- sex
- ALL
- std Ages
- ADULT
- OLDER_ADULT
Treatment arms and interventions
- arm Groups
- description
- Participants will receive 6.0 mg/kg of DS-1062a
- intervention Names
- Drug: DS-1062a
- label
- DS-1062a 6.0 mg/kg
- type
- EXPERIMENTAL
- interventions
- arm Group Labels
- DS-1062a 6.0 mg/kg
- description
- DS-1062a will be administered as an intravenous (IV) infusion once every 3 weeks
- name
- DS-1062a
- other Names
- Datopotamab Deruxtecan
- type
- DRUG
Study design
- allocation
- NA
- intervention Model
- SINGLE_GROUP
- masking Info
- masking
- NONE
- primary Purpose
- TREATMENT
Enrollment
- count
- 137
- type
- ACTUAL
Registered outcome plans (not posted results)
- primary Outcomes
- description
- ORR is defined as the proportion of participants with a best overall response of confirmed complete response (CR) or confirmed partial response (PR) per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.
- measure
- Percentage of Participants With Objective Response Rate (ORR) Based on Blinded Independent Central Review (BICR)
- time Frame
- From baseline until disease progression, death, or other protocol defined reason, up to approximately 24 months.
- secondary Outcomes
- measure
- Duration of Response (DOR)
- time Frame
- From baseline up to approximately 24 months
- measure
- Progression-free Survival (PFS)
- time Frame
- From baseline up to approximately 24 months
- measure
- Overall Survival (OS)
- time Frame
- From baseline up to approximately 24 months
- measure
- Pharmacokinetic Parameter Maximum Concentration (Cmax)
- time Frame
- From baseline up to approximately 24 months
- measure
- Pharmacokinetic Parameter Time to Maximum Concentration (Tmax)
- time Frame
- From baseline up to approximately 24 months
- measure
- Pharmacokinetic Parameter Area Under the Concentration-Time Curve (AUC)
- time Frame
- From baseline up to approximately 24 months
- measure
- Percentage of Participants Who Reported Treatment-emergent Adverse Events (TEAE)
- time Frame
- From baseline up to approximately 24 months
Full study description
- brief Summary
- This is a study of the efficacy, pharmacokinetics, and safety of DS-1062a in participants with advanced or metastatic non-small cell lung cancer (NSCLC) with known actionable genomic alterations.
- detailed Description
- This study will evaluate DS-1062a 6.0 mg/kg in participants with advanced or metastatic NSCLC with actionable genomic alterations and who have been previously been treated with 1 platinum-containing therapy and 1 or more lines of targeted therapy. The study will be divided into 3 periods: Screening Period, Treatment Period, and Follow-up Period. The primary analysis of Objective Response Rate (ORR) by blinded Independent Central Review (BICR) will be conducted after all participants either have been followed for at least 9 months after the start of study treatment or have discontinued from the study, whichever occurs first.
Source references
- references
- citation
- Ahn MJ, Lisberg A, Goto Y, Sands J, Hong MH, Paz-Ares L, Pons-Tostivint E, Perol M, Felip E, Sugawara S, Hayashi H, Cho BC, Blumenschein G Jr, Shum E, Lee JS, Heist RS, Cornelissen R, Chang WC, Kowalski D, Zebger-Gong H, Chargualaf M, Gu W, Lan L, Howarth P, Joseph R, Okamoto I. A Pooled Analysis of Datopotamab Deruxtecan in Patients With EGFR-Mutated NSCLC. J Thorac Oncol. 2025 Nov;20(11):1669-1682. doi: 10.1016/j.jtho.2025.06.002. Epub 2025 Jun 12.
- pmid
- 40516821
- type
- DERIVED
- citation
- Sands J, Ahn MJ, Lisberg A, Cho BC, Blumenschein G Jr, Shum E, Pons Tostivint E, Goto Y, Yoh K, Heist R, Shimizu J, Lee JS, Baas P, Planchard D, Perol M, Felip E, Su WC, Zebger-Gong H, Lan L, Liu C, Howarth P, Chiaverelli R, Paz-Ares L. Datopotamab Deruxtecan in Advanced or Metastatic Non-Small Cell Lung Cancer With Actionable Genomic Alterations: Results From the Phase II TROPION-Lung05 Study. J Clin Oncol. 2025 Apr;43(10):1254-1265. doi: 10.1200/JCO-24-01349. Epub 2025 Jan 6.
- pmid
- 39761483
- type
- DERIVED
Source notices and limitations
Discovery and provenance
- release id
- ctgov-registry-7ad944f6deaf1f5cd6122126
- edge id
- nct-edge-5bfb8c8fa433bb2949e6
- requested nct id
- NCT04484142
- primary nct id
- NCT04484142
- source kind
- fda_spl_label
- source record id
- c5c6cd04-1bea-4809-a830-b1fb1ba94e97
- source file sha256
- a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6
- payload sha256
- 027af2f31fa26dda62409a5fcf0cc8fc2dcaa5206662723cda176ee50d078095
- payload
- application numbers
- BLA761394
- clinical indication matching status
- not_inferred
- end exclusive
- true
- id
- nct-edge-5bfb8c8fa433bb2949e6
- link basis
- explicit_NCT_identifier_in_acquired_source
- nct id
- NCT04484142
- occurrences
- context exact
- tients with locally advanced or metastatic EGFR-mutated NSCLC who were enrolled across two clinical studies: TROPION-Lung05 and TROPION-Lung01. TROPION-Lung05 (NCT04484142) was a global, multicenter, single-arm, open-label trial in patients with previously treated NSCLC with an actionable genomic alteration and TROPION-Lung01 (NC
- end
- 332
- exact text
- NCT04484142
- start
- 321
- offset unit
- unicode_code_points
- source file
- /tmp/cancer-full-research/indications/raw/labels-00600.json
- source file sha256
- a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6
- source json pointer
- /results/58/clinical_studies/0
- source kind
- fda_spl_label
- source record id
- c5c6cd04-1bea-4809-a830-b1fb1ba94e97
- source string basis
- parsed_JSON_string_unmodified
- source string sha256
- 850a9164a370d46ff3a36e2fb4860da7d1e9cac15ce6530089f7631fd6c611e2
- spl effective time
- 20260527
- spl set id
- 2950227c-6230-4ca4-a135-46e44d9424a0
- release id
- ctgov-registry-7ad944f6deaf1f5cd6122126
- edge id
- nct-edge-bb3775cf273d6c57ab87
- requested nct id
- NCT04484142
- primary nct id
- NCT04484142
- source kind
- nci_explicit_reference_or_link
- source record id
- Source null
- source file sha256
- 6c0293d896ac3f4fa1f72bc232cb43756a1127a408b137ddfab0e3cfa54a997a
- payload sha256
- 00ebcc83f342f08a8af14916e00c7f84e87464fe1f6deeef0068fb0358b36132
- payload
- clinical indication matching status
- not_inferred
- end exclusive
- true
- id
- nct-edge-bb3775cf273d6c57ab87
- link basis
- explicit_NCT_identifier_in_acquired_source
- nct id
- NCT04484142
- occurrences
- context exact
- patients in Dato-DXd group and 4.1% of patients in the docetaxel group. </li></ul></div></li><li>The single-arm, open-label, phase II <a href="/clinicaltrials/NCT04484142">TROPION-Lung05</a> (NCT04484142) study enrolled adult patients with stage IIIB, IIIC, or IV NSCLC. Patients had at least one documented activating <em class="
- end
- 674029
- exact text
- NCT04484142
- start
- 674018
- context exact
- 1% of patients in the docetaxel group. </li></ul></div></li><li>The single-arm, open-label, phase II <a href="/clinicaltrials/NCT04484142">TROPION-Lung05</a> (NCT04484142) study enrolled adult patients with stage IIIB, IIIC, or IV NSCLC. Patients had at least one documented activating <em class="gene-name">EGFR</em>, <em class="
- end
- 674062
- exact text
- NCT04484142
- start
- 674051
- context exact
- /ul></div></li><li>A pooled analysis of patients with <em class="gene-name">EGFR</em>-altered NSCLC (n = 117) who received Dato-DXd in <a href="/clinicaltrials/NCT04484142">TROPION-Lung05</a> (n = 78) or <a href="/clinicaltrials/NCT04656652">TROPION-Lung01</a> (n = 39) was completed and findings were published in abstract form.[<
- end
- 676110
- exact text
- NCT04484142
- start
- 676099
- offset unit
- unicode_code_points
- source file
- /tmp/cancer-full-research/nci/raw/11a3437f29dc92742e.html
- source file sha256
- 6c0293d896ac3f4fa1f72bc232cb43756a1127a408b137ddfab0e3cfa54a997a
- source json pointer
- Source null
- source kind
- nci_explicit_reference_or_link
- source record id
- Source null
- source retrieved at
- 2026-09-09T23:21:59.782436+00:00
- source string basis
- UTF-8_text_with_universal_newline_translation
- source string sha256
- 96af5062fe49c6481bdc1ef6946e69939f30c810b02e368845c837ccf6c0977c
- source title
- Non-Small Cell Lung Cancer Treatment (PDQ®)–Health Professional Version
- source update dates
- context
- Updated: May 15, 2025
- datetime
- 2025-05-15T12:00:00Z
- display
- May 15, 2025
- release id
- ctgov-registry-7ad944f6deaf1f5cd6122126
- edge id
- nct-edge-efba4ac5e6a6ef1f26e7
- requested nct id
- NCT04484142
- primary nct id
- NCT04484142
- source kind
- fda_approval_notice
- source record id
- fda-29743855ffd67cd9
- source file sha256
- d23c7d0cb49d26cffe40b7ca5585cf76bc08c0b1ce0af7fa9b63637f973c1052
- payload sha256
- fa7865dea6912166b53f9be32728d02f9eedfdd89de2c111b199981ef184126c
- payload
- clinical indication matching status
- not_inferred
- end exclusive
- true
- id
- nct-edge-efba4ac5e6a6ef1f26e7
- link basis
- explicit_NCT_identifier_in_acquired_source
- nct id
- NCT04484142
- occurrences
- context exact
- ed chemotherapy and received datopotamab deruxtecan-dlnk at the recommended dose across two clinical trials: TROPION-Lung05 and TROPION-Lung01. TROPION-Lung05 (NCT04484142) was a multicenter, single-arm trial, while TROPION-Lung01 (NCT04656652) was a multicenter, open-label, randomized controlled trial.</p><p>The major efficacy o
- end
- 25356
- exact text
- NCT04484142
- start
- 25345
- offset unit
- unicode_code_points
- source event date
- 2025-06-23
- source file
- /tmp/cancer-full-research/updates/pages/fda-grants-accelerated-approval-datopotamab-deruxtecan-dlnk-egfr-mutated-non-small-cell-lung-cancer.html
- source file sha256
- d23c7d0cb49d26cffe40b7ca5585cf76bc08c0b1ce0af7fa9b63637f973c1052
- source json pointer
- Source null
- source kind
- fda_approval_notice
- source record id
- fda-29743855ffd67cd9
- source string basis
- UTF-8_text_with_universal_newline_translation
- source string sha256
- d23c7d0cb49d26cffe40b7ca5585cf76bc08c0b1ce0af7fa9b63637f973c1052
- source title
- FDA grants accelerated approval to datopotamab deruxtecan-dlnk for EGFR-mutated non-small cell lung cancer
Preserved source evidence · Not medical advice